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An Introduction to this Issue 
Paulami Naik and Bonnie Marshall   
Alliance for the Prudent Use of Antibiotics 
A healthy human intestinal tract hosts 10 times as 
many bacteria, as there are cells in the human body. 
Represented in this population are 400 to 1000 
bacterial species distributed among nine phyla. [1,2] 
These bacteria provide us with energy through 
fermentation, produce vitamins for our needs, protect us 
from infection, and ensure proper functioning of our 
immune system. [3] The specific distribution of bacteria 
that colonizes our gut at any given time can have an 
important effect on our health and it can be manipulated 
with the use of ―probiotics‖ and ―prebiotics‖.  
Probiotics are "live micro-organisms that confer a 
health benefit on the host when consumed in adequate 
amounts." [4] The most commonly used and best studied 
probiotics are   species of the bacteria Lactobacillus, 
Bifidobacteria , and Streptococcus and the 
yeast Saccharomyces boulardii-—typically delivered 
singularly or in combination via various yogurt 
preparations, or as supplemental capsules. Less 
frequently, whole fecal transplants from healthy donors 
are utilized as suppositories.  Often discussed in relation 
to probiotics are non-live ―prebiotics‖. Prebiotics are 
―nondigestible food ingredients that beneficially affect 
the host by selectively stimulating the growth and/or 
activity of one or a limited number of bacteria in the 
colon, and thus improve host health.‖ [5] In this issue of 
the APUA Clinical Newsletter, we focus solely on 
probiotics. 
The first formal research on probiotics dates back to 
the early 1900s. In 1907, Russian Nobel laureate, Dr. Elie 
Metchnikoff published The Prolongation of Life in which 
he noted that exceptionally long-lived Bulgarian 
peasants, consumed large quantities of sour milk 
containing Lactobacillus bulgaricus. He wrote, ―The 
dependence of the intestinal microbes on the food makes 
it possible to adopt measures to modify the flora in our 
bodies and to replace the harmful microbes by useful 
microbes." [6] Through this work he established a 
foundation for the study of probiotics.  
With the advent of antibiotics, the interest in 
probiotics lay largely dormant for several decades.  
However, with the resurgence of interest in the gut flora, 
the previous 15 years have witnessed significant 
advances in the characterization of select gut probiotic 
strains and on substantiation of their health claims. 
Current investigations into the human microbiome, such 
as the work of the National Institute of Health‘s Human 
Microbiome Project, are revealing the complexity of the 
organisms inhabiting the human body. Dr. Martin Blaser, 
professor of microbiology at New York University, and 
investigator of the link between gut flora and obesity 
states, ―We‘re still learning how far the impact of the 
microbiome reaches and the costs of perturbing it.‖ [7] 
The interest in the micro biome has advanced the 
probiotic field as individual strains and functions are 
being researched. Nonetheless we are still on the frontiers 
of understanding their specific roles and potential uses. 
Molecular and genetic studies are making significant 
advances in understanding the mechanistic basis 
underlying the benefits s of probiotic strains.  
Relation to Antibiotic Resistance 
Continued or excessive use of antibiotics is known to 
disrupt the normal micro biota of the human body. 
Promptly restoring normal balance of flora following 
treatment is important for preventing unrestrained 
overgrowth of undesirable, multidrug resistant strains 
such as Clostridium difficult and other hospital acquired 
opportunists. Probiotics have emerged as a valuable 
adjunct to antibiotic therapy and as a useful tool in 
avoiding or reducing antibiotic use. Given the recent 
decline in the development of new classes of antibiotics 
and the increase in multi-drug resistant superbugs, the 
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search for additional approaches for treatment and 
prevention of bacterial disease is increasingly urgent.  
Probiotic Use and Safety 
Probiotics are widely considered to be safe for human 
oral and vaginal use and there is a long history of the use 
of fermented milk products with minimal recorded 
reported side effects. The number of probiotic products 
available on the world market is estimated to be over 
2000 [8], but the industry remains largely unregulated 
and unstandardized—making comparative studies 
difficult.  To begin filling this void, scientists have 
formalized groups such as the International Scientific 
Association for Probiotics and Prebiotics (ISAPP), a non-
profit founded in 2002 to raise the scientific credibility of 
the field by working with experts and conducting 
meetings on high quality research. By providing an 
objective, science-based voice, ISAPP hopes to benefit 
the end users of these products by helping them make 
informed choices. [9] ISAPP has endorsed the guidelines 
set by the World Health Organization (WHO) and the 
United Nations Food and Agriculture Organization 
(FAO) for evaluation of probiotics—governing, strain 
designation, efficacy/effectiveness and safety. [4,10]  For 
example, new strains and products should be proven safe 
in human studies amend those bearing some limitations, 
(such as use of S. boulardii [S. cerevisiae]) in patients 
with a leaky gut or other risks) should be clearly labeled. 
[11] 
In the United States, probiotics are currently classified 
as ―dietary supplements‖, (not ―drugs‖) and as such, the 
Food and Drug Administration (FDA) only requires 
premarket notification, with  no demonstrations of safety 
and efficacy required. [12] Due to their overall safety, 
guidelines for use of probiotics in the hospital are 
generally lacking, although some caution is advised for 
use in certain disease states (e.g., severe colitis, bowel 
leaks, neutropenia) where the potential exists for the 
probiotic to enter the blood or peritoneum. [13] Likewise, 
special care should be taken by healthcare personnel who 
handle both probiotic capsules and venous catheters in 
order to avoid transfer to the bloodstream. [12] Of more 
recent interest and concern are safety considerations 
relating to transferable genetic elements that may confer 
antibiotic resistance from the probiotic to pathogenic 
strains, or even to the commensal flora. [14]  
Current Applications and Future directions 
To date, only a very few probiotic strains are well 
researched and tested and most relate to interventions in 
diarrheal illness. Confounding factors in clinical trials 
have undermined and limited the ability to clearly 
determine efficacy for other strains and infectious disease 
states.  Fewer supporting studies exist in the area of 
respiratory disease, but probiotics may offer some 
promise in treating sinusitis, bronchitis, and pneumonia. 
The current lack of rapid diagnostics for upper 
respiratory illness (URI) has led to considerable overuse 
of antibiotics in this area and there is a large potential for 
probiotic intervention. A recent Cochrane meta-analysis 
of 10 clinical trials concluded that probiotic intervention 
exceeded the placebo in reducing episodes of acute URI, 
with some more limited evidence that probiotics could 
reduce the prescription of antibiotics. [15] 
In this issue of the APUA Newsletter, current as well 
as future probiotic applications are examined. Tufts 
University Schools of Nutrition and of Medicine are at 
the forefront of probiotics research and some of their 
experts have contributed articles to this issue. Drs. Barry 
Goldin and Sherwood Gorbach, co-discoverers of 
Lactobacillus GG–the first probiotic proven to colonize 
the gastrointestinal tract—offer an overview of the 
current and proposed uses of probiotics and evaluate the 
strength of supporting evidence. Dr. Shira Doron reviews 
the use of probiotics for prevention and treatment of 
gastrointestinal diseases. Interesting perspectives from 
research in developing countries are provided by Dr. 
Gregor Reid of Western University in Canada and Drs. 
Christine Wanke and Honorine Ward of Tufts Medical 
School, who examine probiotics as useful interventions in 
the vicious cycle of malnutrition and infectious disease 
that severely undermines childhood development.   
In their recognition and endorsement of probiotic 
therapy, the United Nations and World Health 
Organization, issued the call for ―Efforts…to make 
probiotic products more widely available, especially for 
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relief work and populations at high risk of morbidity and 
mortality‖. This call has yet to be ratified by government 
agencies and multinational probiotic companies. With the 
looming global crisis in antibiotic resistance, and a dearth 
of new antibiotics in the pipeline, there persists a critical 
need for adjuncts and alternatives to antibiotic therapy 
that will aid in preserving our severely compromised 
antibiotic treasures.  With their prospects of enhancing 
antibiotic efficacy, alleviating antibiotic side effects, and 
even reducing or eliminating the need for antibiotics, 
coupled with low cost and relative accessibility, 
probiotics offer promise in filling this void, but clearly, 
better designed, more rigorous studies are needed to 
optimize their full potential as interventions, with or 
without antibiotic therapy.  
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Clinical Indications for Probiotics: An 
Overview  
The following article was extracted with permission from a publication of the same title which originally 
appeared in Clin Infect Dis. 2008. 46 (l 2): S96-S100.  This reprint has been updated with new references 
(see Refs 45-48.)  
Barry. R. Goldin, Ph.D. and Sherwood. L. Gorbach, M.D. 
Tufts University School of Medicine, Boston, Massachusetts  
Probiotics have been defined as ―live microorganisms 
which when administered in adequate amounts confer a 
health benefit on the host‖. [1] Probiotics have been used 
to treat a wide range of diseases, ailments, and conditions 
that affect humans and animals. Additional medical 
applications have been proposed for potential future uses, 
depending on the outcomes of future experimental 
studies. The clinical uses of probiotics are broad; 
however, the clinical indications based on evidence-based 
studies are much narrower and are open to continuing 
evaluation. Table 1 contains a partial list of human 
diseases and conditions that probiotics have been used to 
prevent and/or treat.  
The current and proposed uses of probiotics cover a 
wide range of diseases and ailments. An attempt has been 
made to classify the quality of evidence that supports 
these various applications. [44] These classifications 
are based on existing studies, most of which are cited 
in this article, and not on an exhaustive review of the 
entire literature on probiotics. The broad classifications 
include (Table 2) applications with proven benefits, 
applications with substantial evidence that require 
additional support, promising applications that need 
substantial additional evidence, and proposed future 
applications.  
Proven benefits of probiotics include the treatment of 
acute and antibiotic-associated diarrhea; applications 
with substantial evidence include the prevention of 
atopic eczema and traveler's diarrhea; promising 
applications include the prevention of respiratory 
infections in children, prevention of dental caries, 
elimination of nasal pathogen carriage, prevention of 
relapsing C. difficile–induced gastroenteritis, and 
treatment of inflammatory bowel disease; and 
proposed future applications include the treatment of 
rheumatoid arthritis, treatment of irritable bowel 
syndrome, cancer prevention, prevention of ethanol-
induced liver disease, treatment of diabetes, and 
prevention or treatment of graft-versus-host disease.  
The use of probiotics in medical practice is rapidly 
increasing, as are studies that demonstrate the efficacy 
of probiotics. A note of caution should be applied: 
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Table 1. Medical applications in humans 
 for different classes of probiotics.    
Medical condition Class(es) of  
probiotic 
References 
Lactose maldigestion LAB and  
Streptococcus  
Salivarus subsp.  
thermophilus  
[2-5] 
Gastroenteritis   
      Acute diarrhea LAB, Bifidobacterium 




      Antibiotic-associated diarrhea LAB or S. boulardii [18-24] 
      Traveler’s diarrhea  LAB [25,26] 
Allergies LAB [27-31] 
Clostridium difficile-induced colitis LAB [32-34] 
Dental caries LAB [35] 
Intestinal inflammation in children 
      with cystic fibrosis 
LAB [36] 
Respiratory infection in children LAB [37] 
Nasal colonization with pathogens LAB [38] 
Inflammatory bowel disease or  
      irritable bowel syndrome 
LAB [39-43] 
NOTE.    LAB, lactic acid bacteria   
negative findings are being reported, as would be 
expected as more studies are being performed and as 
more applications are being sought for the use of 
probiotics.  
Overall, probiotics appear to be here to stay as part of 
the physician's armamentarium for the prevention and 
treatment of disease; however, more evidence-based 
research is required to firmly establish medical areas of 
use and areas in which probiotics are not applicable.  
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Gut bacteria 
The bacteria in our gastrointestinal tract have an 
important effect on our health. The intestinal microbiota 
can be altered by such interferences as a course of 
antibiotics, or an episode of intestinal infection.  Aberrant 
gut microbiota have been demonstrated not only in 
diarrheal diseases, but also in inflammatory bowel 
disease, irritable bowel syndrome and even in diseases 
which manifest outside the gastrointestinal tract. [1] 
Probiotics 
Living microorganisms have long been used as 
supplements to restore gut health at times of dysfunction. 
They do so not only by changing the intestinal 
microbiota, but also by their immunomodulatory effects 
as well as elaboration of antibacterial substances. 
A probiotic is ―a live microbial food ingredient that, 
when ingested in sufficient quantities, exerts health 
benefits on the consumer‖. [2]  To be considered a 
probiotic, a bacterial strain must be of human origin and 
safe for human use.  Genera represented in this category 
include lactobacilli, bifidobacteria, streptococci, and 
enterococci.  There are many probiotic strains, each with 
unique characteristics.  These have been studied for use 
in the treatment and prevention of a wide range of 
diseases. 
Treatment and prevention of acute diarrhea 
Several meta-analyses and systematic reviews have 
been written on this topic and have found probiotics to be 
effective. [3-7] 
Lactobacillus rhamnosus strain GG (LGG) and 
Lactobacillus reuteri have been the most commonly 
studied probiotics for use in the treatment of acute 
diarrhea in children. [7] The largest study of LGG for 
acute diarrhea in children was conducted by the European 
Society for Paediatric Gastroenterology, Hepatology and 
Nutrition (ESPGHAN) in 2000.  In this study, 287 
children in ten countries ages 1 to 36 months admitted 
with moderate to severe diarrhea were randomized to 
receive either LGG or placebo along with standard oral 
rehydration solution.  The patients who received LGG 
had a shorter duration and decreased severity of illness, 
had a shorter hospital stay and were less likely to have 
persistent diarrhea. [8] 
Shornikova et al performed two smaller studies, one 
randomizing 86 children and one randomizing 40 
children ages 6 to 36 months to Lactobacillus reuteri or 
placebo.  The duration of watery diarrhea was decreased 
in the treated group, as was the percent of subjects with 
persistent diarrhea on day two of illness and the 
frequency of diarrhea on day two. Colonization of the 
intestine by Lactobacillus reuteri was confirmed by stool 
culture.  The larger study, which had higher and lower 
dose arms, also showed a correlation between the dosage 
of L. reuteri and the clinical effect. [9,10] 
Prevention of antibiotic-associated diarrhea and 
gastrointestinal side effects 
Antibiotic-associated diarrhea (AAD) is diarrhea that 
occurs during or shortly after administration of an 
antibiotic, with no other known cause.  The frequency of 
occurrence varies with the antibiotic, but is estimated to 
occur in approximately 25% of the patients receiving 
antibiotics.  The rate of AAD in children may be less, as 
little as 11% in one study, where it was found to be 
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highest (18%) in children under the age of two years. [11]   
McFarland conducted the largest meta-analysis to date 
evaluating 25 randomized controlled trials of probiotics 
for the prevention of AAD including 2810 subjects. [12] 
Of these, 13 (52%) demonstrated a significant reduction 
in the incidence of AAD in the probiotic-treated group 
compared with the placebo group.  Among the studies on 
adults, only 44% had a reduction in AAD in the probiotic 
group, while 67% of the pediatric studies reported a 
benefit in the probiotic group.  Many different probiotic 
strains were used in these trials, including several 
probiotic mixtures, and at various doses.  When these 
analyses were stratified by probiotic strain, only 
Lactobacillus rhamnosus GG, 
Saccharomyces boulardii and the 
various probiotic mixtures had 
significant efficacy. 
Prevention of travelers’ diarrhea 
Diarrhea occurs in 30% to 50% 
or more of travelers to developing 
countries. [13] There have been a 
number of studies on the use of 
probiotics for the prevention of 
travelers‘ diarrhea and the results 
are conflicting. The largest was a Finnish study that 
randomized 756 subjects traveling to two resorts in 
Turkey to take Lactobacillus GG or placebo during their 
stay abroad.  The results from subjects at one of the 
resorts were not statistically different between groups, 
while at the other resort, the LGG group had a 
statistically significant protection rate of 39.5% in the 
first week and 27.9% in the second week. [14] 
Helicobacter pylori infection 
Helicobacter pylori is responsible for such conditions 
as gastritis, peptic ulcers, and gastric cancer.  It colonizes 
the epithelial cells of the stomach and is capable of 
penetrating these cells. In vitro studies have demonstrated 
that various strains of Lactobacillus have antibacterial 
activity against H. pylori [15, 16] and animal studies have 
shown their ability to prevent Helicobacter infection and 
colonization [15, 17-19] and to attenuate gastritis. [19] 
 Lactobacillus acidophilus decreases the viability of 
H. pylori as well as its binding capacity to human 
mucosecreting cells in vitro.  Probiotics have also been 
shown to inhibit urease activity of H. pylori both in vitro 
and in the mouse stomach. [15]  Human studies have 
demonstrated various effects of probiotics on H. pylori 
infection.  Studies have shown a decrease in urea breath 
test values after treatment with probiotics. [20-23] Wang 
et al showed reduced H. pylori density and gastritis 
severity in antral biopsies. [20] 
 More recent studies have focused on probiotics 
as adjunctive therapy to improve the rate of H. pylori 
eradication with standard multi-drug therapy.  Sykora et 
al studied 86 symptomatic H. pylori-positive children 
who were randomized to 
omeprazole, amoxicillin and 
clarithromycin plus or minus 
fermented milk containing 
Lactobacillus casei DN-114 
001. There was a significantly 
enhanced therapeutic benefit 
with the addition of the 
probiotic from 61% to 92%. 
[24] Sheu et al studied 138 
adults who had failed standard 
triple-drug therapy for H. pylori, randomizing them to pre
-treatment for four weeks with yogurt containing 
Lactobacillus acidophilus La5, Lactobacillus bulgaricus, 
and Bifidobacterium lactis Bb12 or no pre-treatment 
followed by quadruple therapy with omeprazole, 
amoxicillin, metronidazole and bismuth subcitrate.  There 
was a significantly higher eradication rate in the pre-
treated group (86% versus 71%). [25] On the other hand, 
in a study of 65 children who tested positive for H. pylori 
in Argentina treated with standard triple therapy followed 
by three months of yogurt (with Lactobacillus casei and 
Bifidobacterium animalis) or milk placebo, no 
differences were seen in the eradication rates at one and 
three months. [26] 
Treatment and prevention of Clostridium difficile 
Clostridium difficile infection can cause a spectrum of 
disease ranging from subclinical infection to severe 
disease including profuse diarrhea, colitis, toxic 
 
“Given the current state of antimicrobial 
resistance and stagnating antimicrobial 
drug development, it is critical to look to 
antibiotic alternatives such as probiotics 
to treat and prevent infections.”  
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megacolon and death.  The disease generally responds to 
therapy with antibiotics but recurrences are common and 
develop in up to one third of patients. These recurrences 
can be refractory to therapy.  Dendukuri et al conducted a 
systematic review on the use of probiotics for prevention 
and treatment of C. difficile-associated diarrhea (CDAD) 
in adults. [27]  Four randomized controlled studies were 
identified with CDAD as the primary outcome. Four 
additional randomized controlled studies identified 
CDAD as a secondary outcome.  Strains studied included 
S. boulardii in 5 of the studies, and different strains of 
Lactobacillus in the other three, one in combination with 
Bifidobacterium.  In these studies, probiotics did not have 
a significant effect on the prevention of CDAD, and only 
two studies showed a benefit for probiotics in treatment 
of CDAD, particularly in patients with more severe 
disease, however the variability in the use of concomitant 
antibiotics against C.difficile make interpretation of the 
results difficult.   
In conclusion, there is considerable need for many 
more well designed trials to be conducted before we can 
fully understand the benefits of probiotics in the 
treatment and prevention of gastrointestinal diseases. 
Each strain must be studied individually for its efficacy in 
each disease state, since results from the study of one 
strain cannot be extrapolated to another. Given the 
current state of antimicrobial resistance and stagnating 
antimicrobial drug development, it is critical to look to 
antibiotic alternatives such as probiotics to treat and 
prevent infections.  
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When I read an article on the BBC online news on 
November 19th, 2004 stating that the World Health 
Organization and Unicef was recommending daily use of 
trimethoprim-sulfamethoxazole for every HIV-positive 
child in Africa, I somewhat despaired at society's  
approach to disease management.  It had been 13 years 
since we had shown that 7 days of antibiotic therapy 
could disrupt the beneficial vaginal microbiota for over 
six weeks [1], and nine and a half years since the British 
Parliament debated the deaths, injuries and other side-
effects of trimethoprim-sulfamethoxazole. While this 
combination is effective at treating many infections, the 
thought that two respected organizations were advocating 
40 billion doses to children  per year seemed madness. 
Given Martin Blaser's recent Nature article highlighting 
the folly of overuse of antibiotics and the critical 
importance of the host's beneficial microbes [2], my 
advocacy of alternative approaches seems justified. 
In hindsight it is ironic that in the same year, 2004, we 
launched a program in Tanzania whereby local mothers 
('mamas') would produce a yogurt supplemented with 
probiotic Lactobacillus rhamnosus GR-1, with the aim of 
improving the quality of life of HIV-positive children and 
adults (Figure 1). [3] The yogurt contains about 9 g of 
protein per serving yielding >15% of the recommended 
daily allowance and 8 g of fat per serving. It is a rich 
source of many micronutrients, including zinc, 
phosphorous, calcium (33% of daily recommendation), 
pantothenic acid, vitamin B12 (>40% of daily 
recommendation), riboflavin and vitamin A (10% of 
daily recommendation). [4] Such is the enthusiasm for 
the program, that the communities have helped set up 
another 11 kitchens in Tanzania and Kenya with more 
planned there and in Rwanda, Burundi and Malawi.  To 
date, these have employed over 60 mamas and farmers, 
been host to 55 student interns from Western University 
in Canada, and led to 26 publications on various aspects 
of the project. In addition, over 20,000 students at 
Western have been engaged in fund raising and 
dissemination of the project. 
Whilst such engagement in Africa is laudable, are 
there health benefits associated with the yogurt intake? 
Answering this required setting up research 
collaborations with various partners, in particular the 
National Institute for Medical Research in Mwanza, and 
performing studies with essentially no funding from 
Canadian government granting agencies.  Nevertheless, 
interesting findings have emerged with administration of 
yogurt and capsules containing L. rhamnosus GR-1 and 
Lactobacillus reuteri RC-14. 
The first study followed 49 male and female adults 
(age 35–45), with 29 receiving the probiotic yogurt (250 
mL daily for 30 days) and 20 not. Five in each group 
were taking anti-retroviral therapy (ART). Compliance 
was good, but on average, participants still missed 3–5 
days yogurt, due to being too sick to travel, lacking a 
family member to assist with program adherence, or fear 
of domestic violence against women who were leaving 
the home to get yogurt. Almost all of the participants had 
marked improvements in their weight, and eight showed 
an improvement in their weight category, moving from 
severely to moderately underweight or from moderately 
underweight to mildly underweight. Significant increases 
were noted in thiamin, riboflavin, biotin, vitamin C, 
pantothenic acid, calcium (p <0.0001), copper, 
phosphorus and potassium. Based upon self-perceptions 
and physician diagnoses, consumers of the probiotic 
yogurt had significantly fewer fungal conditions over the 
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time period of 60 days [r = 0.417, n = 49, p < 0.01], 
fewer episodes of diarrhea [r = 0.372, n = 49, p < 0.01], 
and substantially lower degree of fatigue [r = −0.365, n = 
49, p < 0.01]. This was the first evidence that the yogurt 
might act as a prophylactic against infection. 
The finding has been further supported by an 
observational study. [5] In addition, the prophylactic 
effect in reducing urinary tract infection (UTI) 
recurrences has been confirmed with strains GR-1 and 
RC-14 in capsules administered to elderly Dutch women 
for one year [6], and with Lactobacillus acidophilus 
given to South Korean children with vesicoureteral reflux 
[7], both compared to trimethoprim-sulfamethoxazole. Of 
importance, the GR-1/RC-14 treatment resulted in no 
drug resistance changes compared to the antibiotic treated 
group in whom resistance to trimethoprim-
sulfamethoxazole, trimethoprim, and amoxicillin 
increased within only one month from 20%-40% to 80% 
-95% in E. coli from the feces and urine. [6] Likewise, in 
the study of children, sensitivity of E. coli to  
trimethoprim-sulfamethoxazole was 57.1% in the 
probiotic group and reported as zero in the antibiotic 
group (P<0.019). [7] Such results clearly indicate the 
flaw in the WHO/Unicef approach and the need to retain 
antibiotics for curing infection rather than preventing 
them. Moreover, the findings indicate that probiotics 
need to be included in discussions on how to prevent 
infant deaths from HIV in Africa. Rather than forcing 
African children to take a developed world antibiotic 
every day resulting in that agent no longer being able to 
cure infection because of resistance, would it not make 
more sense to  create locally driven initiatives that take 
advantage of available food sources, stimulate self-
empowerment and deliver fairly similar disease 
prevention? 
The advantages can potentially extend beyond 
preventing infection. One study of 40 patients showed 
superior cure of bacterial vaginosis (BV) with 
intravaginal probiotics versus metronidazole. [8] Studies 
in Nigeria and Brazil have shown that combining 
Lactobacillus GR-1 and RC-14 with antimicrobials can 
improve cure of vaginal infections. [9-12] The effect 
appears to involve creating an environment that restores 
the indigenous lactobacilli as the dominant organisms, 
while in the case of Candida, suppressing fungal growth, 
increasing expression of stress-related genes, lowering 
expression of genes involved in fluconazole resistance 
[13] and up-regulating IL-8 and IP-10 secretion. [14] 
This is a good example of using beneficial organisms to 
counter pathogenic ones. Other examples of this 
phenomenon have been published. [15,16] 
A clinical study using Lactobacillus crispatus CTV-
05 administered intravaginally following metronidazole 
therapy, showed that an ability of the organism to persist 
on the mucosa was associated with significant reduction 
in BV pathogens, Gardnerella and Atopobium. [17]  In a 
randomized, placebo-controlled trial study of HIV-
positive children,  daily use of formula containing 
Bifidobacterium bifidum  with Streptococcus 
thermophilus increased the mean CD4 count (+118 cells 
mm(-3)) compared to -42 cells mm(-3) for children 
receiving  control formula (p = 0.049) (791 cells mm(-
3)). [18] 
In summary, the current medical approach to 
managing infection remains too focused on traditional 
antimicrobial agents and protocols, disregarding their 
side effects and increased resistance. New agents are long 
overdue for conditions such as UTI and BV and for 
patients with chronic diarrhea. Probiotics certainly 
warrant consideration to manage infections and 
Figure 1. The Tukwamuane Women's Group whose Mabatini kitchen 
in Mwanza, launched the Western Heads East probiotic yogurt 
initiative, with production beginning in January 2005. 
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potentially also improve antimicrobial efficacy. The 
social business model used in Africa should be 
considered  in the so-called developed world, where 
poverty, access to adequate care, and poor nutrition all 
contribute to infections continuing to cause widespread 
morbidity and mortality. The success obtained from fecal 
transplant in curing Clostridium difficile caused mostly 
by antibiotic eradication of the gut microbiota [19], 
suggests that the types of probiotics that will be used in 
the future will be different in form and delivery from the 
present. Such a change needs to be aligned with major 
alterations to how probiotics are regulated, and in 
creation of a system understood by lay people as well as 
policy makers. [20] With few side effects and excellent 
patient compliance, HIV positive patients are asking why 
are more foods not targeted to reduce the burden of 
disease? [21] 
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The vicious cycle of infectious diarrheal disease and 
malnutrition is responsible for significant morbidity and 
mortality in children under the age of five years, 
particularly those from low and middle-income countries. 
A recent analysis of child mortality in 2010, estimated 
that worldwide about 60% of the 6.7 million deaths that 
occur in children under the age of five years are caused 
by infectious diseases and that about 10% are due to 
diarrhea. [1, WHO] Malnutrition is estimated to 
contribute to over one third of child deaths. In 2010, 
about 20 million children worldwide were estimated to 
suffer from severe acute malnutrition, 171 million 
children below five years of age were stunted, and 104 
million were underweight. [WHO]   
While malnutrition may occur throughout the 
childhood years, it may be presumed that loss of weight 
or inability to grow may have more of an impact the 
earlier it occurs. Such early malnutrition may be referred 
to as growth faltering. There is no clear definition of 
growth faltering, but it is widely assumed to begin around 
the time of weaning in low and middle income countries 
and is generally assessed by weight-for-age (WAZ), 
height-(or length)-for age (HAZ) and weight-for-height 
(WHZ) Z scores. [WHO] An analysis of the WHO 
Global Database on child growth and malnutrition of 39 
nationally representative data sets from recent growth 
monitoring programs in developing countries [2] found 
the following: For children in the developing world at 
birth, in comparison to the National Center for Health 
Statistics (NCHS), the average weight-for-age, length-for
-age, and weight-for-length are quite close to the 
Probiotics for Diarrheal Disease and Malnutrition 
in Children in Resource-Poor Countries 
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reference. Growth faltering then occurs, so that by 18 
months, mean weight-for-age values and mean length-for
-age values are between 1 and 2 standard deviations 
below the reference median value.   
The three primary growth parameters (WAZ, HAZ, 
WHZ) show different patterns. Mean weight starts to 
falter about 3 months of age, and declines rapidly until 12 
months.  Between 12 and 19 months this decline slows. 
Most wasting (assessed by WAZ score) in children 
occurs in the period between 3 to 15 months of age. For 
length, although the mean birth values are close to the 
NCHS standard, faltering starts soon after birth and lasts 
well into the third year, and is not recovered thereafter. 
These processes appear to be independent of each other 
and the pattern is remarkably similar in multiple 
developing countries.   
Current recommendations are that weaning occurs 
from 4-6 months onward, as foods other than breast milk 
are introduced into the diet. [3, 4] Initiation too early 
displaces breast milk, decreases mother‘s milk production 
and results in malnutrition, while weaning too late leads 
to growth faltering and depressed immune function. 
Regardless of the timing, in situations where 
environmental contamination is high, weaning exposes 
the infant to high levels of enteric pathogens and 
increased morbidity and mortality secondary to infectious 
disease and malnutrition. Multiple studies from 
developing countries have shown that diarrheal disease 
significantly increases at about 6 months of age, 
secondary to increased exposure of the infant to 
pathogens as a result of weaning initiation. [3-6] 
    16 The APUA Newsletter Vol. 30. No. 2 • © 2012 APUA 
Contamination of water is common and this water is used 
in preparation of weaning foods. Contamination of foods 
after cooking also occurs.   
A malnourished child or a child who is frequently 
exposed to enteric pathogens is at higher risk of 
developing diarrheal disease. [7-11] Recent studies 
suggest that acute watery diarrhea accounts for perhaps 
one third of all deaths from diarrhea and dysentery for 
another 20%. Persistent diarrhea (PD) is the greatest 
problem, accounting for approximately 45% of childhood 
deaths from diarrhea. [5, 12, 13] A malnourished child is 
at increased risk for an episode of acute diarrheal disease 
to become prolonged. [14] In spite of the fact that only 10
-16% of episodes of acute diarrhea progress to PD, the 
mortality associated with PD is 
disproportionately high. [12, 13] 
Malnourished children with PD 
had a higher risk of death from PD 
than better-nourished children 
within the same community. [15] 
There is also evidence that 
children who develop PD are 
subsequently at risk for more 
episodes of diarrhea than children who have never had an 
episode of PD. [13, 16-18]   
Probiotics are viable bacteria, which colonize the 
intestine and modify the intestinal miroflora and their 
metabolic activities with a beneficial effect for the host. 
[19-21] Lactobacillus rhamnosus, strain GG (LGG) 
(ATCC 53013), is an extensively studied probiotic strain. 
LGG has been used as therapy in several randomized, 
placebo-controlled trials of acute pediatric diarrhea with 
success. [22-25] LGG has been proven successful in 
decreasing the duration of childhood diarrheal illnesses 
for which the pathogen was not known, in studies done in 
the developing world.  In Northern Pakistan, LGG was 
shown to significantly reduce the duration of acute 
diarrheal illness in hospitalized children compared to 
those treated with placebo. [26] LGG was able to 
significantly reduce the duration of acute watery diarrheal 
illnesses in children in Thailand when compared to 
placebo. [27] LGG has also been effective in treating 
diarrhea caused by C. difficile in children and in elderly 
adults with relapsing diarrhea [28, 29, 50-52]. Likewise, 
it has been used to prevent diarrhea.  A study of the 
ability of LGG to reduce diarrhea in undernourished 
Peruvian children suggests that there were fewer episodes 
of diarrhea in the children who received the probiotic. 
[55] Additionally, LGG has also been shown to enhance 
the immunogenicity of oral vaccines. [30]  
Other studies of LGG suggest that it permits healing 
of the intestinal mucosa by reducing gut permeability and 
by enhancing local intestinal immune responses as well 
as by reconstituting the intestinal flora. [31-33] Although 
the effect of LGG on growth faltering and malnutrition 
has not been extensively studied, the beneficial impact of 
LGG on intestinal integrity and the ability of LGG to 
reduce the total days of diarrhea 
are the basis for the hypothesis 
that LGG will reduce the 
incidence of growth faltering. The 
microbial communities in the 
gastrointestinal tract consist of 
over 1000 species and outnumber 
human cells tenfold. [34] These 
communities, known as the 
―microbiota‖ and their collective genomes, the 
―microbiome‖, play a major role in maintaining gut 
homeostasis, contributing to nutrition and promoting 
resistance to infection by preventing colonization with 
pathogens, modulating innate and adaptive immune 
responses, preserving intestinal mucosal integrity, 
controlling inflammation and contributing to nutritional 
status. Perturbation of the intestinal microbiota is 
associated with impaired nutritional and immune status, 
increased susceptibility to infection, and adverse clinical 
outcomes. Culture-independent and other high 
throughput technologies, including next generation 
sequencing and mass spectrometry, have enabled rapid 
and accurate characterization of the intestinal 
microbiome, metagenome, metatransciptome and 
metabolome in various physiological as well as 
pathological states, such as obesity and inflammatory 
bowel disease.   
Recently, alterations in the intestinal microbiota and 
their metabolic activities have been implicated as playing 
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“Thus, interventions such as probiotics 
may be most effective during 
pregnancy and the first two years of 
life, the so-called “first 1000 days” 
and may need to target pregnant 
women in addition to their infants. “ 
a role in malnutrition as well as in environmental 
enteropathy in children in developing countries. [35, 36] 
Although further studies need to be done to confirm this 
possibility, this finding raises the possibility that in 
addition to provision of adequate quantity and quality of 
nutrients, restoration of the gut microbiome to a more 
―healthy‖ state with the use of tailored probiotics [34, 37-
8] may have a beneficial effect on malnutrition and 
growth faltering in children in resource-poor areas.  
Stunting in these children occurs very early in life and is 
thought to be initiated during pregnancy and intrauterine 
growth.  Thus, interventions such as probiotics may be 
most effective during pregnancy and the first two years of 
life, the so-called ―first 1000 days‖ and may need to 
target pregnant women in addition to their infants.  
Thus far, probiotic approaches have employed single, 
or a combination of a few, beneficial bacterial species.  
However, the likelihood that multiple microbes are 
involved in contributing to the health of the microbiome 
and the recent success of ―fecal transplants‖ [39] suggest 
that these approaches may need to be customized to 
include multiple microbes with defined metabolic 
activities for specific disease states.  The use of 
―designer‖ probiotics that are engineered to block 
deleterious receptor-ligand interactions of pathogenic 
organisms with host cells [40] may also be useful to 
target enteric infections that contribute to the vicious 
cycle of infectious diarrhea and malnutrition. 
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Report from the Field:  
Antibiotic stewardship in Bulgaria – 
achievements and further needs 
Antibiotic Regulation 
In Bulgaria, the Ministry of Health (MH) is the main 
regulator and the Bulgarian Drug Agency (BDA) is 
responsible for drug licensing and control. In order to be 
introduced to the market, an antibiotic needs an 
application and assessment. This procedure is based upon  
EU rules and the license lasts five years. The MH 
organizes a Commission to select drugs to be bought and 
reimbursed by the National Health Insurance Fund 
(NHIF).  
One achievement in 2010 was the strengthening of 
control by the BDA on over-the-counter sales of 
antibiotics through inspections and penalties. But because 
the industry perceives Bulgaria‘s market as unattractive, 
important antibiotics such as the group of penicillinase-
resistant penicillins, colistin, amphotericin B and 
nitrofurantoin are lacking. For example, nitrofurantoin is 
not licensed in Bulgaria and patients must travel abroad 
and buy the drug from Greece or Turkey.  
Finally, there is one new option in the 2011due to the 
changes in the Law for Drugs for Human Usage. The 
hospitals may now apply for antibiotics not available on 
Bulgarian market— if they have been licensed in other 
EU countries, and if the hospitals can provide data that no 
alternatives are available.  
Another important issue is the price of antibiotics. It 
was found that many drugs imported or produced by 
Bulgarian manufacturers are being sold in Bulgaria at 
higher prices than in the other countries. This question 
was recently considered by the new Minister of Health 
and the president of the NHIF. 
Antimicrobial Resistance Surveillance 
The National Antimicrobial Resistance Surveillance 
(ARS) in Bulgaria dates back to 1998. A National 
Reference Laboratory on Quality Control in 
Microbiology and Antimicrobial Resistance Surveillance 
was created at the National Center for Infectious and 
Parasitic Diseases. The Laboratory organizes external 
laboratory control twice a year  and contributes to the 
standardization of antimicrobial susceptibility testing. 
Microbiology laboratories in Bulgaria mandatorily 
participate in the ARS system BulSTAR. Some hospital 
laboratories also participate in the European 
Antimicrobial Resistance Surveillance Network (EARS-
Net) project coordinated by the European Centre for 
Disease Prevention and Control (ECDC). Many have 
Emma Keuleyan, M.D., Ph.D. 
Medical Institute of the Ministry of the Interior 
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Table 1. Hospital antibiotic consumption in 










2001 25 29.7   
2002 20 45.9   
2003 23 42.8   
2004 28 46.2   
2005 30 51.8   
2006 27.5 44.5 40.2 
2007 30 54.0 35.8 
2008 37 26.7 41.3 
2009   44.1 41.9 
2010   49.9 40.1 
2011     36.3 
Units: DDD/100-bed-day 
1. Indiscriminated use of ceftriaxone (since 2006) represents 99% of the 3rd 
generation cephalosporins and accounts for ~50 % of systemic antibiotics.[1]  
2. Rank of antibiotic groups, 2010 in DDD/100 bed-day:  
penicillins – 11.1, cephalosporins – 17.4 , penems – 0.3, MLS – 4 
aminoglycosides – 3.2, fluoroquinolones – 4.0, 
glycopeptides – 0.2, imidazoles – 3.0  
3. Relative antibiotic group use: penicillins:10-43 %, cephalosporins: 13-42 %, 
MLS: 6-8 %, fluoroquinolones: 10-12 %, aminoglycosides: 4-9%, others:1-3 %. [3] 
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traditions in ARS: they collect, analyze and interpret 
hospital ARS data and periodically publish booklets, with 
informational and educational content, that serve policy-
makers. [1,2] The most problematic resistant organisms 
in Bulgaria are the ESBL-producing Enterobacteriaceae 
and multidrug-resistant non-fermenters.  
Antibiotic Consumption 
Most of the laboratories that participated in the 
Antibiotic Resistance Prevention And Control (ARPAC) 
project organized by the European Society of Clinical 
Microbiology and Infectious Diseases (ESCMID), 
continue to survey the antibiotic usage. Table 1 and 2  
provide an extract from antibiotic use in several hospitals.  
In general, antibiotic consumption in Bulgaria remains 
high, and is characterized by an increase in the usage of 
third generation cephalosporins and fluoroquinolones, the 
antimicrobial agents contributing most to the selection of 
resistant strains. 
Antibiotic Stewardship 
Bulgaria was one of the first countries to develop  a 
National antibiotic policy. In 1999 an expert committee, 
along with the Ministry of Health (majority of the 
representatives from APUA), started the Program for 
Antimicrobial Resistance Surveillance and Rational 
Antibiotic policy, approved by the MH in 2001. The 
change of government, however, delayed the immediate 
introduction of this program: several years later it has 
been executed only in part, due to the lack of financial 
support. 
Today, a hospital‘s antibiotic policies form an integral 
element of its accreditation of hospitals. Clinical 
microbiologists, as leaders of a multidisciplinary 
antibiotic team, are charged with responsibility of the 
program. Each hospital has a list of essential antibiotics. 
In general, the policy is restrictive. In the Medical 
Institute, Ministry of the Interior, there are three levels of 
antibiotic prescribing, instituted after discussion with all 
clinicians. Each clinical department elaborates its own 
clinical guidelines for the use of antibiotics. Several 
audits of antibiotic prescriptions have been conducted, 
which has contributed to the amelioration of antibiotic 
usage. Annual Reports from the Clinical Microbiology 
laboratory about ARS and antibiotic consumption are 
being presented and discussed at hospital Medical 
Council. Despite these activities, and every-day 
consultations, the results are suboptimal. One reason is 
the epidemiologic situation in the country. Furthermore, 
rational antibiotic therapy necessitates the optimal dosage 
regimen of the most effective antibiotic, and not giving 
preference to cheaper one. Keep in mind that Bulgaria is 
one of the countries with the lowest GDP in Europe, and 
as such the funds for health-care are smaller. Another, not 
completely achieved aim is the very early start of 
appropriate therapy for severe systemic infections. 
In practice, antibiotic stewardship is not easily 
achieved. It requires stricter infection control, improved 
regulation, increased investment, and support from the 
government and international organizations. 
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Table 2.  Antibiotic usage in 2011 in Pediatric  





Fluoroquinolones 5.3 Carbapenems 0.5 
Tetracyclines 0.2 Cephalosporins 21.2 
MLS 6.3     1st generation 10.8 
  Macrolides 5.8     2nd generation 0.2 
  Lincosamides 0.5 3rd generation 10.0 
Co-trimoxazole 0.8     4th generation 0.2 
Penicillins 8.5 Aminoglycosides 2.9 
  with extended spectrum 2 Imidazoles 4.1 
  with anti-pseudomonas 
activity and β-
lactamase inhibitor 
6   
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58,000 hits to the English website alone from 177 
different countries and territories. The website also 
receives a large number of hits from non partner 
countries, for example, the Portuguese website has had 
as many hits from Brazil as Portugal.  
Lecky DM, Hawking MKD, McNulty CAM. e-Bug – Making Microbiology 
and Hygiene Child‘s Play. Microbiology Today. 2011 May: 112-7. 
APUA-Nepal Update 
APUA-Nepal will be making two presentations at the 
First International Conference on Infectious diseases and 
Nanomedicine 2012 scheduled for December 15-18, 
2012 in Kathmandu, Nepal. The topics of the 
presentation are ―Common Isolates and their 
Antibiogram in T.U Teaching Hospital (TUTH), a 
tertiary care hospital in Nepal‖ and ―Efforts of APUA-
Nepal in Reducing the Emergence and Spread of 
Resistance.‖ 
APUA-Australia 
APUA-Australia will be hosting its annual meeting 
―Antimicrobials 2013‖ from February 21 to 23, 2013 in 
Sydney, Australia. Dr. Peter Davey, University of 
APUA-UK Update 
Dr. Cliodna McNulty, President of APUA-United 
Kingdom and her team have developed the  
‗e-Bug‘ Website, a European wide antibiotic and 
hygiene teaching resource for junior and senior school 
children. The project not only reinforces an awareness of 
the benefits of antibiotics, but also teaches prudent 
antibiotic use, and how inappropriate use can have an 
adverse effect on an individual's good microbes and 
antibiotic resistance in the community. An article 
published in Microbiology Today provides details on the 
development of this website and the resources it 
provides. 
For 2012 the team have developed seven  new online 
games for students (see below) and two lesson plans for 
teachers covering farm hygiene (junior schools) and 
chlamydia (senior schools). 
The e-Bug partnership consists of 24 countries 
providing united health messages, with the resources 
being translated into all EU languages and also Turkish. 
In the 2011-2012 academic year there have been over 
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Senior resource characters 
Viruses      Bacteria  Fungi 
New Games in 2012 
Soapy Soakers: Be a microbe buster on the skin! (Hand hygiene)  
Bogey Bus: What‘s the best way to stop germs spreading in a sneeze (Respiratory Hygiene)  
Chicken Surprise: How safe is the food you cook? (Food Hygiene)  
Doctor Doctor!: Can you treat the patient before the time runs out! (AMR)  
Mixed-up Microbes: There are three types of microbes, but do you know which is which?  
Happy Holidays: Get your holiday vaccine before the holiday viruses get you (Vaccinations)  
Body Busters: Kill the body bugs before they get you. Remember – antibiotics don‘t kill viruses!  
APUA Chapter Reports 
APUA-Cuba Update 
APUA-Cuba continues to grow, with more than 1,400 
members in over 60 medical specialties. Dr. Moisés 
Morejón (Manual Fajardo Hospital) and his colleagues 
have held multiple symposia on antimicrobial resistance 
and the need for new antibiotics. One of its recent 
conferences discussed the applicability of modern 
diagnostic technology in detecting HAI pathogens and 
identifying resistant phenotypes in immunocompromised 
patients. 
APUA-Cuba has proposed national guidelines, citing 
APUA recommendations for correct antibiotic use in 
critical-care patients in the face of rising rates of HAIs 
and infection from multidrug-resistant Acinetobacter 
baumannii. Other proposed guidelines include those for 
antibiotic use in surgical prophylaxis, and  parameters for 
sequential antibiotic therapies that will hopefully evolve 
into sophisticated antibiotic stewardship programs.  
Pneumonia is another growing concern in Cuba, 
especially in children, and has stimulated discussions on 
the importance of correct diagnosis and provided an 
incentive for pneumococcal vaccine development. APUA
-Cuba has evaluated international guidelines for 
community-acquired pneumonia, citing guidelines from 
IDSA/ATS and the South American working groups 
ConsenSur and SEPAR as being the most useful. 
This year Dr. Morejón published Enfermedades 
Tropicales Mayores: Enfermedades Olvidadas o 
Desatendidas (Forgotten & Neglected Tropical 
Diseases).  
Dundee in Scotland will be presenting the plenary 
―Antimicrobials Stewardship‖, and Drs. Louis Rice, 
Brown University and Fred Tenover, Cepheid in the 
USA will be presenting ―Rapid Diagnostics and 
Appropriate Antibiotic Use‖ and ―Molecular Diagnostics 
for Infectious Diseases: From DNA Probes to Whole 
Genome Sequencing, An Insider‘s Perspective‖ 
respectively. Dr. Matthew Cooper from the University of 
Queensland will be presenting the plenary ―New 
Antimicrobial Discovery: Promise versus Reality?‖ 
APUA-Georgia Update 
APUA-Georgia was established in 2003 and  
managed by Professor Alexander Nanuashvili until his 
death in October 2011. His wife, Dr. Tamar Davitashvili 
has since assumed leadership of the chapter. 
In 2009, Prof. A. Nanuashvili published the volume 
"Bacterial Infections", which has been of paramount 
importance for Georgian physicians and microbiologists. 
Through 2010-2011, before his severe illness, Prof. 
Nanuashvili conducted many seminars for Georgian 
doctors in the field of prudent use of antibiotics. In 2010, 
Prof. Nanuashvili headed the creation of the country‘s 
monitoring system and  associated data bases of 
antimicrobial resistance. In the same year, APUA-
Georgia conducted a national conference on antibiotic 
resistance in order to review the  data gathered  for the 
antibiotic resistance monitoring system. 
Prof. Nanuashvili‘s final work "Antimicrobial 
Agents‖, will shortly be published in the form of a 
periodical newsletter for circulation among doctors. 
Since 2011, APUA- Georgia has been taking part in the 
Study for Monitoring Antimicrobial Resistance 
Trends (SMART) being conducted by the International 
Health Management Associates, Inc (IHMA) to monitor 
worldwide antimicrobial resistance trends among aerobic 
and facultatively anaerobic Gram-negative bacilli (GNB) 
isolated from intra-abdominal infections. 
In 2012, APUA-Georgia has been conducting 
seminars for doctors on topics related to antibacterial 
therapy. Soon, they plan to analyze the data collected by 
the national resistance monitoring system. 
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Attendees of the Symposium held for establishment of  APUA-
Mayabeque sub-chapter. APUA-Cuba has created sub-chapters 
in 9 out of Cuba‘s 16 provinces. 
 
APUA Leadership Award 2012 
 
Professor Roman S. Kozlov, M.D., M. Sc., D.Sc. 
And APUA-Russia 
 
The Alliance for the Prudent Use of Antibiotics (APUA) is pleased to present the 2012 
APUA Leadership Award to Professor Roman S. Kozlov and APUA-Russia for sustained 
leadership to contain antibiotic resistance in Russia and the adjacent region. This award also 
recognizes the Chapter‘s collaborative efforts with the Inter-Regional Association for 
Clinical Microbiology & Antimicrobial Chemotherapy (IACMAC) and the Institute of 
Antimicrobial Chemotherapy (IAC) of Smolensk State Medical Academy (SSMA).  
As President of APUA-Russia, Professor Kozlov has led the remarkable efforts of this 
chapter to promote the prudent use of antibiotics. APUA-Russia has been extensively 
involved in activities throughout Russia, Belarus, Ukraine, and other countries of the Former 
Soviet Union for the establishment of a network of sentinel laboratories and organization of 
continuous surveillance programs of both community and hospital-acquired pathogens. 
APUA-Russia is based at SSMA in Smolensk, where Professor Kozlov serves as IAC 
Director. Collaboration with the IAC has provided the laboratory facilities to develop the 
surveillance work. The results of these studies have been used as a basis for development of 
national guidelines on the management of community-acquired pneumonia, hospital-acquired 
pneumonia, intra-abdominal infections, and skin and soft-tissue infections.  
This year, the APUA Leadership Award recruited nominations for an outstanding young 
professional who has demonstrated extraordinary leadership. Professor Kozlov was 
recommended for this award by Dr. Stephen A. Lerner of Wayne State University and a 
member of APUA‘s Scientific Advisory Board. Professor Kozlov assumed leadership of the 
APUA-Russia chapter at a young age and has successfully brought to fruition many of the 
goals first envisioned by his mentor and predecessor, Dr. Leonid Stratchounski. In his letter 
of nomination, Dr. Lerner indicates, 
―This award and these accomplishments stand on the vision of Dr. Leonid 
Stratchounski whose untimely death in June 2005 was a grave tragedy for the 
world‘s interests in antibiotics and resistance. Fortunately, part of Dr. 
Stratchounski‘s vision was to identify promising young people in Smolensk 
and to groom them for excellence in the field of antibiotics. The prime example 
is Dr. Roman Kozlov. Dr. Kozlov became Dr. Stratchounski‘s lieutenant, and 
he was successfully able to assume the leadership positions he holds today.‖ 
    24 The APUA Newsletter Vol. 30. No. 2 • © 2012 APUA  
 
Professor Kozlov also serves as President of IACMAC, an organization that has been a 
beacon for epidemiologic, clinical and basic research on antibiotics and their appropriate 
usage. The efforts of IACMAC to communicate their research to scientists and practitioners 
across the expanse of the Former Soviet Union has a provided a great service to the field of 
infectious disease. Notably, IACMAC has developed an interactive ‗Map of Antimicrobial 
Resistance of Russia‘ available freely on the web site www.antibiotic.ru for the use of 
physicians and microbiologists throughout the world. Furthermore, IACMAC has organized 
an exemplary distant education course on antimicrobial therapy which has been successfully 
completed by more than 600 physicians.  
APUA is pleased to recognize Professor Kozlov‘s leadership and his success in 
influencing the prudent use of antibiotics in Russia and the region. In offering his 
congratulations Dr. Stuart B. Levy, President of APUA stated, ―Roman Kozlov represents a 
class of emerging young leaders whose dedication is essential to ensure antibiotic 
effectiveness. His leadership demonstrates the value of the APUA global network and its 
affiliated chapters in 66 countries throughout the world.‖   
While APUA's traditional ICAAC reception was not held this year, the award was  
presented to Professor Kozlov at a special Leadership Award dinner at ICAAC co-hosted by 
Drs. Thomas F. O‘Brien and Stephen A. Lerner of APUA. The dinner was attended by 
representatives from some of corporate sponsors. We plan the traditional APUA reception at 
next year's ICAAC in Denver, Colorado and will be formally recognizing Professor Kozlov 
and APUA-Russia then.   
 
For a list of previous award winners, please see the APUA website. 
 
APUA-Russia is organizing the  II Volga Region Conference on Antimicrobial Therapy in Samara, 
Russia from October 11-12, 2012. The program in English can be viewed here. 
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New APUA report: Expert advice for 
antibiotic stewardship programs  
APUA surveyed members from the APUA Scientific 
Advisory Board regarding strategies for effective 
implementation of antibiotic stewardship programs (ASP) 
in healthcare facilities. They pointed out both technical 
and perceptual challenges to successful implementation 
of ASPs and some ways to overcome these 
obstacles. Contributing experts were:  
Thomas F. O‘Brien, M.D. (Brigham and Women‘s 
Hospital) 
Shira I. Doron, M.D. (Tufts Medical Center)  
Philip D. Walson, M.D. (Geörg-August-Universität 
School of Medicine; Clinical Therapeutics) 
Alfred DeMaria, Jr., M.D. (Massachusetts 
Department of Public Health)  
Read the results of this survey on the APUA website. 
More information on this topic is available in the 
following past APUA Newsletters: 
Enhancing Infection Control with Antibiotic 
Stewardship (Vol.29 No.3) 
Antibiotic Stewardship Gaining Traction: 
Recommended Models and Resources (Vol.29 No.1) 
Antibiotic Stewardship Programs: Proven Strategies 
to Preserve Medicine‘s ―Magic Bullets‖ (Vol.24 
No.1) 
Additional resources are found on our website under 
For Practitioners: Treatment Guidelines and Stewardship 
APUA signs letter to the US Congress 
requesting $547 million for BARDA 
 The letter is addressed to the House and Senate 
Appropriations Committees and asks for an appropriation 
of at least $547 million for Fiscal Year 2013 for the 
Biomedical Advanced Research and Development 
Authority (BARDA) . BARDA is intended to provide ―an 
integrated, systematic approach to the advanced 
development and purchase of necessary medical 
countermeasures (MCMs), including vaccines, biological 
and small molecule therapeutics, antiviral drugs, 
antifungal drugs, and antibiotics, diagnostics, respiratory 
devices, and other medical supplies.‖ Although the 
program has been underfunded since its inception, 
investments by BARDA have resulted in the 
development of new therapeutics such as a new smallpox 
antiviral and vaccine for HIV patients, anthrax treatments 
as well as progress toward developing new anthrax 
recombinant vaccines. Since private investment in 
antibiotic research and development has plummeted, 
BARDA has become an important source of funding for 
research and development of novel antibiotics for 
treatment of multi-drug resistant pathogens.  
APUA Leadership Statement advocates 
strengthening FDA Draft Guidance on 
antibiotic use in livestock 
The FDA Draft Guidance #213 (―Recommendations 
for Drug Sponsors for Voluntarily Aligning Product Use 
Conditions with Guidance for Industry #209‖)  asks drug 
companies to voluntarily remove "growth promotion" 
from the lists of FDA-approved uses on their products‘ 
labels and instead list disease treatment, control, or 
prevention. This guidance was open for public comment 
until July 12, 2012. 
APUA, in partnership with PEW Charitable Trusts has 
been advocating for stricter drafting and enforcement of 
this guidance. APUA commented on the guidance in the 
form of an organizational letter urging the FDA to make 
this change in labeling practices an enforceable rule 
rather than a recommendation. The letter also encouraged 
the FDA to remove "disease prevention" from the list of 
approved uses, because allowing it can, in practice, be 
identical to allowing the use of antibiotics for "growth 
promotion".   
In addition, APUA developed a leadership 
statement addressed to President Obama and FDA 
Commissioner Hamburg. APUA reached out to 
colleagues for support and this statement was signed by 
21 leaders in science and medicine including 4 Nobel 
Laureates and 5 ASM Presidents. Please see statement on 
the following page. 
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APUA Headquarters in Action 
Stuart Levy, MD  
ASM* Past President 
Francisco J. Ayala, PhD 
AAAS** President  
Mario Capecchi, PhD 
2007 Nobel Laureate 
Julian Davies, PhD  
ASM Past President 
Walter Gilbert, PhD  
1980 Nobel Laureate  
Michael S. Gilmore, PhD  
Sir William Osler Professor 
 
Carol Greider, PhD 
2009 Nobel Laureate 
James Hughes, MD 
Professor, Immediate Past-
President, IDSA*** 
George Jacoby, MD  
Head, Infectious Disease, 
Lahey Clinic 
Molly Jahn, PhD 
Professor, former Deputy Under 
Secretary for USDA 
Michael Katz, MD  
Professor Emeritus 
Gerald T. Keusch, MD 
Professor, Former Director 
Fogarty Center, NIH 
Calvin Kunin, MD, MACP 
Emeritus Professor of Medicine 
Stephen A. Lerner, MD  
Professor of Medicine 
Jay Levy, MD 
Professor, Head of Laboratory, 
AAAS & AAM**** Fellow 
Jeff F. Miller, PhD 
ASM President 
 
Richard Novick, MD 
Professor of Microbiology and 
Medicine 
Stanley Prusiner, MD 
1997 Nobel Laureate 
Moselio Schaechter , PhD  
ASM Past President 
Thomas Schmidt, PhD 
2011 President Elect ASM 
Alexander Tomasz, PhD 
Professor, Head of Rockefeller 
Laboratory 
 
Chief  Executive Officers 
Stuart B. Levy, President 
Thomas F. O’Brien, Vice President 
Kathleen T. Young, Executive 
Director 
Board of  Directors 
Stuart B. Levy, Chairperson 
Harris A. Berman 
Gordon W. Grundy 
Bonnie Marshall 
Thomas F. O’Brien 
Arnold G. Reinhold 
Stephen C. Schoenbaum 
Philip D. Walson 
Mary Wilson 
Scientific Advisory Board 
Jacques F. Acar, France 
Werner Arber, Switzerland 
Fernando Baquero, Spain 
Michael L. Bennish, USA 
Patrice Courvalin, France 
Otto Cars, Sweden 
Jose Ramiro Cruz, Guatemala 
Iwan Darmansjah, Indonesia 
Julian Davies, Canada 
Paul Farmer, Haiti 
Walter Gilbert, USA 
Herman Goossens, Belgium 
Sherwood L. Gorbach, USA 
Ian M. Gould, Scotland 
George Jacoby, USA 
Sam Kariuki, Kenya 
Ellen L. Koenig, Dominican Re-
public 
Calvin M. Kunin, USA 
Jacobo Kupersztoch, USA 
Stephen A. Lerner, USA 
Jay A. Levy, USA 
Donald E. Low, Canada 
Scott McEwen, Canada 
Jos. W.M. van der Meer, The Neth-
erlands 
Richard P. Novick, USA 
Iruka Okeke, USA & Nigeria 
Maria Eugenia Pinto, Chile 
Vidal Rodriguez-Lemoine, Vene-
zuela 
José Ignacio Santos, Mexico 
Mervyn Shapiro, Israel 
K. B. Sharma, India 
Atef  M. Shibl, Saudi Arabia 
E. John Threlfall, United Kingdom 
Alexander Tomasz, USA 
Thelma E. Tupasi, Philippines 
Anne K. Vidaver, USA 
Fu Wang, China 
Thomas E. Wellems, USA 
Bernd Wiedemann, Germany 
July 10, 2012 
 
President Barack Obama            and  The Honorable Margaret Hamburg, MD 
1600 Pennsylvania Ave. NW  Commissioner, Food and Drug Administration 
Washington, DC 20500   10903 New Hampshire Avenue 
     Silver Spring, MD 20993-0002 
 
Dear President Obama and Commissioner Hamburg: 
 
As recognized leaders in the U.S. scientific and medical community, we applaud the FDA’s 
recent actions to promote judicious use of antibiotics in food-producing animals through 
recommendations, delineated in its guidance documents.  We support your guidance that antibiotics not 
be used for growth promotion and feed efficiency, and that there be veterinary oversight in the 
dispensing of antibiotics—particularly in feed and water, where whole herds and flocks are the recipients.  
These voluntary guidances represent a significant shift in U.S. public health protection, as they begin to 
address the high risks that non-judicious use of antimicrobials in animals pose for human health – in the 
form of increases in drug resistance and potential treatment failures. We are concerned, however, that 
they are insufficient and that stronger regulation is needed.  
 
There is no reason to expect compliance from agribusiness, in view of its long history of 
rebuffing regulatory efforts to curb antibiotic use. In addition, FDA considers use of antibiotics for 
disease prevention to be a therapeutic use, essential to animal health. Since many drugs that have been 
approved for growth promotion purposes have also been approved for routine disease prevention, we 
are concerned that industry will not reduce overall antibiotic use, but merely shift from growth 
promotion to prevention.  We request that FDA address antibiotics used for prevention and recommend 
and provide incentives for using alternative strategies, such as vaccines, probiotics, and improved 
management practices, for disease prevention and control. We suggest that further guidance clearly 
describe plans for monitoring progress.  Specifically, the further development of our national 
antimicrobial resistance monitoring system to include more geographic representation and species-
specific data on resistance and antimicrobial use in animals and humans would go a long way to inform 
and evaluate practitioner compliance and outcomes. 
 
According to the U.S. CDC and WHO, antimicrobial resistance is one of the top five public 
health threats.  What is needed is an overall reduction in antimicrobial use, achieved by offering 
economic incentives to adopting alternatives in conjunction with further regulatory and legislative action.  
We strongly support the passage of the Preservation of Antibiotics for Medical Treatment Act (PAMTA, 
H.R. 1549, S.619), which would withdraw the use of seven classes of antibiotics that are critically 
important to human health from food animal production, unless specific disease conditions apply.   Now 
is the time to act. Thank you for your consideration. 
 
Sincerely yours, 
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HIVMA and IDSA Update Policy 
Recommendations for HIV 
In conjunction with the July 2012 International AIDS 
Conference, the Infectious Disease Society of America‘s 
(IDSA) Center for Global Health Policy and HIV 
Medicine Association (HIVMA)  featured the 2012 HIV 
compendium, Clinical Issues in HIV Medicine, and 
updated policy recommendations (PDF) following the 
HPTN 052 study, the first large‐scale, randomized 
controlled trial showing that antiretroviral therapy 
reduces the risk of sexual transmission of HIV to an 
uninfected partner. 
IDSA Updates Group A Strep Treatment 
An update to the 2002 clinical practice guideline for 
the diagnosis and management of group A streptococcal 
pharyngitis was made by the Infectious Diseases Society 
of America in September 2012 (see Clinical Infectious 
Diseases). 
In order to deter inappropriate use of antibiotics, the 
guideline advises that once a strep infection is confirmed 
by testing, penicillin or amoxicillin, not cephalosporin 
should be used as first-line therapy. The IDSA also 
recommends that children who suffer  recurrent strep 
throat should not have their tonsils surgically removed 
solely to reduce the frequency of infection. 
A podcast with the lead author has been developed 
and other tools, such as mobile device and pocket-card 
formats for use at the point of care, are in development 
(see IDSA: practice guidelines section). 
CDC Updates STD Guidelines 
According to the new guidelines published in the 
Center of Disease Control and Prevention‘s Morbidity 
and Mortality Weekly Report in August 2012, oral 
cephalosporins are no longer recommended for gonorrhea 
treatment. The rationale for this change is provided by 
recent data from CDC's Gonococcal Isolate Surveillance 
Project that demonstrate a significant increase (17-fold 
from 2006 to 2011) in the percentage of Neisseria 
gonorrhoeae isolates showing tendency for cefixime 
resistance. CDC recommends that doctors immediately 
stop routine use of cefixime. In order to preserve the last 
remaining antibiotic considered highly effective for 
gonorrhea treatment,  combination therapy with 
intramuscular ceftriaxone, plus either oral azithromycin 
or doxycycline, is now recommended for uncomplicated 
cases. If ceftriaxone is not used due to complications, a 
test of cure is recommended one week after treatment.  
Since cefixime and ceftriaxone are in the same class 
of antibiotics, it is only a matter of time before the fast- 
mutating N. gonorrhoeae develop resistance to 
cephalosporin as well. Although there are no documented 
treatment failures in the United States, untreatable 
gonorrhea has already been reported in Asia and Europe. 
In case of treatment failure under current guidelines, the 
CDC should be notified within 24 hours. A specimen 
should be collected for culture and sensitivity, and the 
patient should be re-treated. The patient‘s recent partners 
should also be treated.  
Tufts Studies Novel Storage Medium for 
Antibiotics and Vaccines 
Conventional methods of antibiotic and vaccine 
storage depend on refrigeration to maintain their potency.  
In resource-poor settings, however, cold storage is not 
always available. For example, after six months at 25°C, 
conventionally freeze-dried MMR (measles, mumps, 
rubella) vaccine retains only 60-75% of its potency, and 
becomes virtually useless at 45° C.  
Dr. David Kaplan and his team have described a new 
technique for packing antibiotics and vaccines (July issue 
of the Proceedings of the National Academy of Sciences) 
that involves boiling silk cocoons in sodium carbonate to 
extract silk fibroin. The fibroin is then treated with salt 
and preservative and spread out into sheets and freeze-
dried. With this new silk sheet packing, the MMR 
vaccine retains about 85% of it‘s potency after six 
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News and Publications of Note 
 
months, regardless of temperature.  Similar results were 
seen with tetracycline, and penicillin. Vaccines and 
antibiotics stored in this silk fibroin matrix are yet to be 
tested in humans, but the risk of adverse effects is 
minimal given that silk, often used in sutures, is harmless 
to people. 
CDDEP’s Visualization Series Focuses on 
Two Antibiotic Resistance Topics 
The Center for Disease Dynamics, Economics and 
Policy website hosts a visualization series that examines 
correlations between outpatient prescribing rates of oral 
vancomycin and C. difficile mortality in the United 
States. The strength of the relationship suggests that drug 
utilization data can be a cost-effective tool for disease 
surveillance. 
Another item in this visualization series focuses on the 
alarming increase in retail sales of carbapenem antibiotics 
in India and Pakistan. Without the enforcement of strict 
regulation curbing over the counter sales, there is a grave 
risk that resistant organisms will emerge and become 
almost impossible to treat.  
New UN Reports highlight progress on 
child survival 
The UN Inter-agency Group for Child Mortality 
Estimation (UN-IGME) has released new data showing 
that the reduction in the pace of child deaths has 
accelerated sharply since 2000. Similar trends are noted 
in the  UNICEF‘s Report: Committing to Child Survival: 
A Promise Renewed – Progress Report 2012, which 
summarizes mortality estimates along with the top killers 
of children under five, and outlines the practical 
strategies that are needed to accelerate progress. Indeed, 
progress has been made over the last two decades—-
thanks to sound strategies, adequate resources and, above 
all, political will. 
Bringing diagnostics to resource-poor 
settings 
 Utilizing a fictitious but dramatic case-in-point 
example, Michael Ingerson-Mahar brings to life the dire 
scenarios of real-life people whose lack of access to point
-of-care diagnostic tests (POCTs) in the developing world 
can mean the difference between life and death (Microbe, 
Sept 2012). In Sept 2011, the American Academy of 
Microbiology (AAM) convened a panel 
of microbiologists, engineers, epidemiologists and public 
health officials to consider questions surrounding the 
myriad, complex steps involved in the design and 
development of POCTs.  Their report, "Bringing the Lab 
to the Patient: Developing Point-of-Care Diagnostics for 
Resource Limited Settings" discusses the impacts that 
POCTs could have on clinical decision-making and 
highlights the need for interactive discourse between the 
many players who must collaborate effectively to bring 
promising POCTs to remote areas.   Many obstacles must 
be surmounted to achieve the ideal qualities of a POCT 
for these sites: i.e., affordable, sensitive, specific, user-
friendly, robust and rapid (ASSURED), as well as 
integration into the larger health care system.  Matching 
the needs of decision-makers at resource poor locations 
with the new technologies that are emanating from the 
research community is a current challenge. Deficits in 
communications channels that exist between the two, 
coupled with regulation and licensing issues, present 
enormous hurdles to overcome. Efforts spearheaded by 
the journal Lab on a Chip and the Foundation for 
Innovative New Diagnostics (FIND), for example, are 
making progress towards filling these gaps. 
CDC Funds Help Prevent HAIs 
The Affordable Care Act has allowed funding of 
infrastructure to implement state-based health care-
associated infection (HAI) prevention programs. Sixteen 
states are receiving funds for building multi-facility 
prevention initiatives. Previous investments have resulted 
in saved lives and health care costs in 21 states, 
demonstrating significant reductions in HAIs. Four states 
will receive funding for advancing the national 
implementation of electronic laboratory records. The 
funds will improve capacity to receive, validate, process, 
and use incoming electronic laboratory records messages 
in surveillance systems and ensure timely reporting of 
health care-associated infections to CDC‘s National 
Healthcare Safety Network. 
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Upcoming Events 
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September 29- October 4, 2012: ASM's 6th Conference on Biofilms in Miami, FL. 
 
October 11-12, 2012: The Interregional Association for Clinical Microbiology and Antimicrobial 
Chemotherapy's II Volga Region Conference on Antimicrobial Therapyin Samara, Russia. 
 
October 17-21, 2012: IDSA's inaugural IDWeek will be held in San Diego, CA. IDWeek is the first-
ever combined meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare 
Epidemiologyof America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious 
Diseases Society (PIDS).  The theme of this year’s meeting is “Advancing Science, Improving Care” and 
will feature the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and 
epidemiology of infectious diseases, including HIV, across the lifespan. 
 
October 22-26, 2012: ASM's 4th Conference on Beneficial Microbes in San Antonio, TX. 
 
October 27-31, 2012: APHA's 140th Annual Meeting and Expo will be held in San Francisco, CA on 
the topic of "Prevention and Wellness Across the Life Span." The APHA meeting attracts more than 
13,000 national and international physicians, administrators, nurses, educators, researchers, 
epidemiologists, and related health specialists to address current and emerging issues in health science, 
policy, and practice. 
 
November 12-18, 2012: CDC's Get Smart About Antibiotics Week.  
 
November 27-28, 2012: World Animal Health Congeress in Kansas City, MO. 
 
February 4-8, 2013: Tufts CSDD “Postgraduate Course in Clinical Pharmacology, Drug Development 
and Regulation” in Boston, MA. 
 
February 21-23, 2013: Australian Society for Antimicrobial's Annual meeting “Antimicrobials 2013” 
in Sydney, Australia. 
 
March 14, 2013: British Soceity for Antimicrobial Chemotherapy's Spring Meeting 2013 in London, UK.  
www.apua.org The Alliance for the Prudent Use of Antibiotics 
About Us 
 
Antibiotics are humanity's key defense against disease-causing microbes. The growing prevalence of antibiotic 
resistance threatens a future where these drugs can no longer cure infections and killer epidemics run ram-
pant. The Alliance for the Prudent Use of Antibiotics (APUA) has been the leading global non-governmental 
organization fighting to preserve the effectiveness of antimicrobial drugs since 1981. With affiliated chapters 
in more than 66 countries, including 33 in the developing world, we conduct research, education and advo-
cacy programs to control antibiotic resistance and ensure access to effective antibiotics for current and fu-
ture generations.  
 
Our global network of infectious disease experts supports country-based activities to control and monitor 
antibiotic resistance tailored to local needs and customs. The APUA network facilitates the exchange of ob-
jective, up-to-date scientific and clinical information among scientists, health care providers, consumers and 
policy makers worldwide. 
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